This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Gastric pH in Critically Ill Patients

This study has been completed.
Information provided by:
Medical University of Vienna Identifier:
First received: December 26, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted
H2-receptor antagonists are the gold standard for stress ulcer prophylaxis in critically ill patients. Various studies demonstrated superiority of proton pump inhibitors over H2-receptor antagonists in increasing gastric pH and in healing gastric acid-dependent diseases. It is unknown, whether proton pump inhibitors are more effective in increasing gastric pH than H2-receptor antagonists in critically ill patients requiring stress ulcer prophylaxis.

Condition Intervention Phase
Critically Ill Patients Indication for Stress Ulcer Prophylaxis Drug: esomeprazole Drug: ranitidine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study.

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • the percentage of time with gastric pH > 4 [ Time Frame: 72 hours ]

Secondary Outcome Measures:
  • median gastric pH [ Time Frame: 72 hours ]
  • incidence of gastrointestinal bleeding [ Time Frame: 72 hours ]
  • incidence of ventilator associated pneumonia [ Time Frame: ICU stay ]
  • the percentage of time with an gastric pH > 5 [ Time Frame: 72 hours ]

Enrollment: 75
Study Start Date: July 2004
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
patients with indication for stress ulcer prophylaxis and gastric pH < 4
Drug: esomeprazole
40mg once daily
Active Comparator: 2
patients with indication for stress ulcer prophylaxis and gastric pH < 4
Drug: ranitidine
50mg every h hours

Detailed Description:
Gastric pH is measured continuously for 72 hours with a pipolar microelectrode placed between 7 and 15cm below the lower esophageal sphincter.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • critically ill patients
  • indication for stress ulcer prophylaxis
  • gastric pH < 4

Exclusion Criteria:

  • gastrointestinal bleeding
  • gastric pH > 4
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00590928

Medical University of Vienna, Department of Medicine III, ICU
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Christian Madl, MD Medical University of Vienna
  More Information

Responsible Party: Christian Madl, MD, Medical University of Vienna Identifier: NCT00590928     History of Changes
Other Study ID Numbers: 13H1-CM1
ESORAN trail
Study First Received: December 26, 2007
Last Updated: December 26, 2007

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes
Ranitidine bismuth citrate
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Histamine H2 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on July 27, 2017